Thursday January 18th 2018

Biogen’s new MS drug approved by FDA will be made in RTP

The long-acting multiple sclerosis treatment that the U.S. Food and Drug Administration approved late last week will be manufactured in Research Triangle Park. The drug, Zinbryta, will be manufactured by Biogen (Nasdaq: BIIB), which is based in Cambridge, Massachusetts, and has a major production outfit in RTP. Bingen received FDA approval for the once-a-month treatment together with AbbVie (NYSE: ABBV). Although Zinbryta showed higher efficacy in treating MS, Biogen recommends that patients take… (Source: bizjournals.com Health Care:Biotechnology headlines)

Originally from: 

Biogen’s new MS drug approved by FDA will be made in RTP

Leave a Comment

More from category

6,000-year-old track record for healing leaky gut
6,000-year-old track record for healing leaky gut

When I was traveling in India, I had the privilege of studying Ayurvedic medicine with traditional Master Healers. [Read More]

Study shows high-salt diet causes dementia in mice
Study shows high-salt diet causes dementia in mice

A high-salt diet reduces resting blood flow to the brain and causes dementia in mice, according to a new study by [Read More]

What you should know about neurosarcoidosis
What you should know about neurosarcoidosis

A look at neurosarcoidosis, an inflammatory disease that can affect most organs in the body. Included is detail on [Read More]

Depression and fatigue in multiple sclerosis: relation to exposure to violence and cerebrospinal fluid immunomarkers – Brenner P, Granqvist M, K…
Depression and fatigue in multiple sclerosis: relation to exposure to violence and cerebrospinal fluid immunomarkers – Brenner P, Granqvist M, K…

Multiple sclerosis (MS) is a neuroinflammatory condition characterized by chronic dysregulation of immune responses [Read More]

Your NEJM Group Today: MS Review / HIV PrEP for Women / Texas Medical Director Opportunity
Your NEJM Group Today: MS Review / HIV PrEP for Women / Texas Medical Director Opportunity

Here's what we selected for you today: NEJM Clinical Practice Center: Review: A number of interventions to modify the [Read More]